Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 17/20 | 0.50 |
| ▸ | PGR | P06401 | 5/20 | 0.49 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29455838 | 0.81 | NR3C1 (0.48) | NR3C1PGRCYP11B2 | |
| SCHEMBL21057611 | 0.81 | NR3C1 (0.48) | NR3C1PGRCYP11B2 | |
| SCHEMBL10124514 | 0.78 | NR3C1 (0.49) | NR3C1PGRCYP11B2 | |
| SCHEMBL15485207 | 0.77 | PGR (0.53) | NR3C1PGRCYP11B2 | |
| SCHEMBL15485188 | 0.76 | NR3C1 (0.47) | NR3C1PGR | |
| SCHEMBL22225746 | 0.75 | NR3C1 (0.74) | NR3C1PGRCYP11B2 | |
| SCHEMBL15485104 | 0.75 | CYP11B1 (0.50) | NR3C1CYP11B2 | |
| SCHEMBL10124275 | 0.73 | NR3C1 (0.49) | NR3C1PGRCYP17A1CYP1A2 | |
| SCHEMBL5135413 | 0.73 | CYP11B2 (0.71) | NR3C1PGRCYP11B2 | |
| SCHEMBL24924163 | 0.72 | NR3C1 (0.60) | NR3C1PGRCYP1A2CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2018-12-27 | — | — | US | disclosed |
| EP-2888261-B1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. | 2016-07-07 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181241-B2 | Antagonists of chemokine receptors | CHEMOCENTRYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2655371-B1 | PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2015-02-25 | — | — | EP | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CHEMOCENTRYX, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-8546442-B2 | Pyrazolopiperidine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546442-B2 | Pyrazolopiperidine compounds as CCR1 receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
| WO-2012087782-A1 | PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160193191-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | NR3C1 122/4885PGR 1391/4885CYP17A1 3446/4885 |
| US-20180369213-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | NR3C1 122/4885PGR 1391/4885CYP17A1 3446/4885 |
| US-20120322790-A1 | Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | NR3C1 181/4885PGR 1354/4885CYP17A1 2315/4885 |
| US-20140057937-A1 | ANTAGONISTS OF CHEMOKINE RECEPTORS | CCR1, CCR3, CCR2 | NR3C1 122/4885PGR 1391/4885CYP17A1 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.